Citigroup’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
VCM
VPM
Citigroup's DNLI Position: Q1 2026 in Review
Citigroup increased its Denali Therapeutics (DNLI) stake by 27% in Q1 2026, buying an estimated $166K and bringing the position to 39,278 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #3293.
Citigroup first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $7.85M in Q1 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Citigroup held 39,278 shares of Denali Therapeutics worth $754K as of Q1 2026.
- Citigroup bought 8,333 Denali Therapeutics shares in Q1 2026, an estimated $166K.
- Denali Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3293 holding.
- Citigroup first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Citigroup's Denali Therapeutics position peaked at $7.85M in Q1 2024.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.